体外血液净化与心脏手术急性肾损伤:SIRAKI02随机临床试验
在西班牙2家三级医院开展的双盲随机临床试验,纳入343例非急诊心脏手术且CSA-AKI高风险患者,比较体外血液净化(EBP)装置连接体外循环回路与标准护理。EBP组CSA-AKI发生率为28.4%,标准护理组为39.7%(P=.03),校正差异为10.4%(95%CI,2.3%-18.5%;P=.01)。
要点
- 非选择性EBP装置连接体外循环回路可显著降低非急诊心脏手术患者术后7天内CSA-AKI发生率。
- EBP组CSA-AKI发生率为28.4%,标准护理组为39.7%,校正差异为10.4%。
- 预设临床次要终点或事后探索性终点大多数未见显著差异,两组不良事件追踪无差异。
核心结论
- 在非急诊心脏手术人群中,将非选择性EBP装置连接体外循环回路与术后7天内CSA-AKI的显著降低相关。
研究设计与样本
- 双盲随机临床试验,在西班牙2家三级医院开展。
- 纳入18岁及以上、接受非急诊心脏手术且CSA-AKI高风险的患者,入组时间为2016年6月15日至2021年11月5日,随访数据截至2022年2月5日。
- 共评估1156例患者,343例按1:1随机分配接受EBP或标准护理。
主要发现
- 343例随机患者中,EBP组169例,标准护理组174例;平均(SD)年龄为69(9)岁,女性119例。
- EBP组CSA-AKI发生率为28.4%(95%CI,21.7%-35.8%),标准护理组为39.7%(95%CI,32.3%-47.3%)(P=.03)。
- 采用对数二项模型校正后差异为10.4%(95%CI,2.3%-18.5%)(P=.01)。
- 大多数预设临床次要终点或事后探索性终点未见显著差异(P>.05)。
- 敏感性分析中,EBP在合并慢性肾脏病、糖尿病、高血压、左心室射血分数低(<40%)和体重指数较低(<30)的患者中降低CSA-AKI更为有效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cardiac surgery-associated acute kidney injury (CSA-AKI) remains a significant problem following cardiopulmonary bypass (CPB). Various strategies are proposed to attenuate CSA-AKI, including extracorporeal blood purification (EBP), but little is known about the effect of EBP through an acrylonitrile-sodium methallylsulfonate/polyethyleneimine membrane during CPB. OBJECTIVE: To determine whether the use of an EBP device in a nonemergent cardiac surgery population reduces CSA-AKI after CPB. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, randomized clinical trial was conducted in 2 tertiary hospitals in Spain. Patients 18 years or older undergoing nonemergent cardiac surgery who were at high risk for CSA-AKI were enrolled from June 15, 2016, through November 5, 2021, with follow-up data through February 5, 2022. Of 1156 patients assessed, 343 patients were randomized (1:1) to either receive EBP or standard care. INTERVENTION: Nonselective EBP device connected to the CPB circuit. MAIN OUTCOMES AND MEASURES: The primary outcome was the rate of CSA-AKI in the 7 days after randomization. RESULTS: Among 343 patients randomized (169 to receive EBP and 174 to receive usual care), the mean (SD) age was 69 (9) years and 119 were females. The rate of CSA-AKI was 28.4% (95% CI, 21.7%-35.8%) in the EBP group vs 39.7% (95% CI, 32.3%-47.3%) in the standard care group (P = .03), with an adjusted difference of 10.4% (95% CI, 2.3%-18.5%) using a log-binomial model (P = .01). No significant differences (P > .05) were observed in most of the predefined clinical secondary end points or post hoc exploratory end points. In a sensitivity analysis, EBP was found to be more effective in terms of CSA-AKI reduction in patients with chronic kidney disease, diabetes, hypertension, low left ventricular ejection fraction (<40%), and lower body mass index (<30). No differences were observed between the groups in adverse events tracking. CONCLUSIONS AND RELEVANCE: The use of a nonselective EBP device connected to the CPB circuit in a nonemergent population of patients undergoing cardiac surgery was associated with a significant reduction of CSA-AKI in the first 7 days after surgery. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02518087.
引用
- Pérez-Fernández X, Ulsamer A, Cámara-Rosell M, et al. Extracorporeal Blood Purification and Acute Kidney Injury in Cardiac Surgery: The SIRAKI02 Randomized Clinical Trial. JAMA. 2024. PMID: 39382234. doi:10.1001/jama.2024.20630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。